Articles by Anna Rose Welch

31. Will Pay-For-Performance Really Suit The Cancer Drug Space? 6/9/2015

    If Express Scripts should have its way, what would happen to inter-industry competition between the pharma players — specifically in the cancer space? If price tags are altered based off a drug’s performance, it seems to me the industry and its ways of quantifying success and leadership in the market will be faced with change as well — but it’s not entirely clear it will be what Express Scripts had in mind.

32. Industry-Academia Partnerships: Is Big Pharma Getting Riskier With Its R&D? 6/3/2015

    There’s a new partnership under way in the quest for the long-sought-after cure for HIV. Last month, GSK teamed up with the University of North Carolina at Chapel Hill to form a research institute and a company dedicated to finding a cure for HIV and AIDS. GSK will shell out $4 million annually over the next five years to launch the research center on Chapel Hill’s campus.

33. FDA News Roundup: Valeant, Pfizer, Boehringer Ingelheim, And More 5/29/2015

    What FDA decisions have you missed recently?

34. FDA News Roundup: Baxter, Celgene, Agios, And More 5/22/2015

    What FDA decisions have you missed recently?

35. FDA News Roundup: Vertex, Merck KGaA , Bayer, And More 5/15/2015

    What recent FDA decisions have you missed lately?

36. What's The Hang Up With Drug Cost Transparency? Blame It On “Innovation” 5/12/2015

    A few months ago, a study came out examining the escalating costs of cancer treatments, which, no secret here, have left payers, patients, and lawmakers increasingly agitated and demanding answers.

37. FDA News Roundup: Biogen Idec, GSK, Roche, And More 5/8/2015

    What regulatory decisions have you missed lately?

38. Breakthrough Therapy Designation: Worth The Development Time Crunch, Experts Say 5/4/2015

    When I hear the words “Breakthrough Therapy Designation” (BTD), I immediately picture a gold-embossed certificate with a blue ribbon. After all, the designation is reserved for those candidates that, early on in clinical studies, promise more extraordinary benefits than the current standard-of-care treatments for a disease. Judging from the recent buzz I’ve noticed in the industry, the increasing number of treatments boasting this designation is in no way eliminating its prestige.

39. FDA News Roundup: Kythera Bio, Boehringer Ingelheim, GW Pharma, And More 5/1/2015

    What recent FDA decisions did you miss?

40. Clinical Trial Data Transparency: The Dangers Of “Putting It In Layman's Terms” 4/27/2015

    It’s been an exciting and tumultuous few months for ALS patients and the small biotech Genervon. The lengthening saga among the company, the FDA, and the army of eager, treatment-seeking ALS patients culminated recently in an order from the FDA that Genervon publicly release all data from the Phase 2 trial of its ALS candidate GM604. In a statement released early this week, Genervon said it had submitted all required data to the FDA for review.